Introduction
Atherosclerosis and its acute clinical sequelae such as myocardial infarction are caused by multiple risk factors.! There is a consensus that by tackling risk factors (eg, by not smoking2 and by lowering low-density lipoprotein cholesterol), and by using antiplatelet agents or betablockers the probability of myocardial infarction will be reduced. A retrospective analysis of hypertensive patients suggested that high renin levels may predict myocardial infarction or stroke6 and a prospective study of 1717 hypertensive patients reported that a high renin profile was associated with higher rates of both myocardial infarction and death? However, it is not clear whether the increases in plasma renin reflected the extent of underlying myocardia dysfunction secondary to (fig 1) ) Table I provides details on rates of fatal and non-fatal myocardial infarction separately and in combination with cardiac and total mortality. Risk reductions for myocardial infarction were similar in both trials (23% in the treatment trial, p < 002; 24% in the prevention trial, p < 0-01). At the end of the two trials, 362 (10-6%) patients in the placebo group had had a myocardial infarction compared with 288 (8-5%) in the enalapril group (risk reduction 23%, 95% interval [CI] 11-34%; p < 0-001). The reduction in nonfatal myocardial infarction appeared to be larger (29%) than the reduction in fatal myocardial infarction (14%), but the CIs of these estimates overlap substantially and provide no evidence of heterogeneity. (fig 4) . 25% of all deaths in the study were preceded by an interim myocardial infarction. Even after exclusion of deaths during the first 7 days after an infarction, mortality was higher in those who had an interim infarction (RR 3-5, 95% CI 2-9-4-2). The 12-month rates of hospital admission for heart failure were 20-5% and 8-6% respectively (RR2-1, 95% CI 1-6-2-6). For the 1094 patients with unstable angina, the 1-year mortality rate was 14-6% compared to 90% among the 5703 patients without unstable angina (RR 1-4,95% CI 1-2-1-6) (fig 4) . The Myocardial infarction was a secondary endpoint specified in the protocol; hospital admission for angina was not and there are no objective criteria for the diagnosis of unstable angina, so data on this endpoint should be cautiously interpreted. However, the differences observed in unstable angina are likely to be unbiased because the diagnosis was made blind and the data were collected prospectively on standard forms. The reduction in unstable angina was significant in each trial and the combined data from both trials are highly significant. The Although our data are based on patients with low ejection fraction, the observation of benefit in subgroups defined by level of ejection fraction, aetiology, and against a background of different drugs raises the possibility of a wider role for ACE inhibitors in preventing major ischaemic events in other populations. This hypothesis should be tested in trials of patients with hypertension or other risk factors that predispose to infarction and among patients with ischaemic heart disease and preserved ventricular function.
A list of SOLVD investigators and centres -has been publishes. 9 The study was largely funded by the US National Heart, Lung and Blood Institute with additional contributions from Merck, Sharpe and Dohme, which had no involvement in the design, conduct, analysis, or interpretation of the data.
